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Abstract
We consider the effects of parameter uncertainty on the optimal radiation schedule in the
context of the linear-quadratic model. Our interest arises from the observation that if inter-
patient variations in normal tissues and tumor sensitivities to radiation or sparing factor of the
organ at risk (OAR) are not accounted for during radiation scheduling, the performance of the
therapy may be strongly degraded or the OAR may receive a substantially larger dose than
the maximum threshold. This paper proposes two radiation scheduling concepts to incorporate
inter-patient variability into the scheduling optimization problem. The first approach is a robust
formulation that formulates the problem as a conservative model that optimizes the worst case
dose scheduling that may occur, assuming that the parameters vary within given intervals. The
second method is a probabilistic approach, where the model parameters are given by a set of
random variables. Our probabilistic formulation insures that our constraints are satisfied with
a given probability, and that our objective function achieves a desired level with a stated prob-
ability. We used the same transformation as [37] to reduce the resulting optimization problem
to two dimensions. We showed that the optimal solution in the absence of uncertainty in the
tumor radio-sensitivity parameters (α and β) occurs at one of the corners of the feasible region.
However if we incorporate uncertainty in α and β into the optimization problem, this result
does not hold anymore. In this case, we showed that the optimal solution lies on the boundary
of the feasible region and we implemented a branch and bound algorithm to find the global
optimal solution. We demonstrated how the configuration of optimal schedules in the presence
of uncertainty compares to optimal schedules in the absence of uncertainty (conventional sched-
ule). We observed that if the number of fractions in the optimal conventional schedule is the
same as the robust and stochastic solutions, it is preferable to administer equal or smaller total
dose. In addition if there exist more (fewer) treatment sessions in the probabilistic or robust
solution compared to the conventional schedule, a reduction in total dose squared (total dose)
will be expected. Finally, we performed numerical experiments in the setting of head-and-neck
tumors including several normal tissues to reveal the effect of parameter uncertainty on optimal
schedules and to evaluate the sensitivity of the model to the choice of key model parameters.
Keywords: Robust Optimization, Radiotherapy, Nonlinear Programming,
Linear-Quadratic Model
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1 Introduction
The building block for virtually all mathematical models of radiation response is the linear-quadratic
model (LQ), which matches well with experimental data across a wide range of clinically relevant
radiation doses and fractionation schemes ([15] and [5]). The basic model states that if a collection
of cells is exposed to N fractions of radiation, di Gy (SI derived unit of ionizing radiation) in i
th
fraction, the reproductively viable fraction of cells after the exposure is given by e−
∑N
i=1 αdi+βd
2
i .
The two parameters α and β depend on the specific tissue that is being irradiated. The parameter
α represents killing of cells from a single track of radiation, and β represents the killing of a cell
via two independent tracks of radiation [17]. There are several mathematical extensions to the
LQ framework to incorporate additional biological phenomena such as repopulation of the tumor
population between fractions, re-oxygenation of the tumor (this is required for some radiation
therapy to be effective), the effectiveness of DNA repair mechanisms between fractions, and the
redistribution of tumor cells within the cell cycle. Taken together these four extensions are often
referred to as the ‘4Rs’ and there have been several works based on these extensions [45].
When radiotherapy is used in the clinical setting, it is necessary to ensure that the treatment
avoids excessive toxicity in normal tissues in the vicinity of the tumor. Therefore it is necessary to
ensure that the radiation absorbed by the surrounding normal tissue falls within desired constraints.
Hence the ultimate goal in radiotherapy is maximizing tumor damage while ensuring that the level
of normal tissue toxicity does not exceed a given threshold. The standard approach for measuring
tumor damage and tissue toxicity is via the linear quadratic model and the biologically equivalent
dose (BED), respectively ([15] and [16]).
Most radiation treatments are currently administered in equal fractions five days a week, for
6 weeks total. Over the past few decades there have been several mathematical works that have
studied the survival benefit of various fractionation schedules for a wide range of cancers. In [6],
that most other radiobiological make similar time-dose predictions as the LQ formalism. In that
work they used the LQ model in combination with Lea-Catcheside time factor, which takes into
account dose protraction or fractionation and DNA repair between fractions. Yang and Xing ([47])
explored the influence of the ‘4Rs’ of radiobiology on external beam radiotherapy for fast and
slowly proliferating tumors and conclude that including repair effects in the BED model may give
rise to optimal non-uniform fractionation schedules. Mizuta et al. ([27]) presented a mathematical
model that minimizes the radiation effect on the late responding normal tissues while keeping the
effect of radiation on the tumor constant. They showed that the multi-fractionated irradiation
with a constant dose is better if the ratio of
(
α
β
)
Normal Tissue
/
(
α
β
)
Tumor
is less than the ratio of
the dose received by the normal tissue, while Hypo-Fractionated irradiation is better otherwise.
Unkelbach et al. ([43]) studied the interdependence of the optimal fractionation scheme and the
spatial dose distribution in the normal tissues. In particular, they derived a criterion under which
a Hypo-Fractionated regimen is indicated for both parallel and serial OARs. In a very recent work
[36], a formulation of the optimal fractionation problem that includes multiple normal tissues has
been considered. They established sufficient conditions under which equal-dosage or single-dosage
fractionation is optimal. In recent work ([21]) the authors investigated optimal fractionation for a
mouse model of glioblastoma, in this work they found that non-standard fractionation schedules
lead to improved survival times; a finding that was verified in experimental studies. In [2] this work
was extended to include a richer set of toxicity constraints.
Until very recently, there was no work that precisely described the optimal fractionation sizes in
the presence of multiple normal tissues. In particular, most works considered the optimal schedule
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with respect to a single normal tissue. However in practice, there are usually at least two healthy
structures in the vicinity of the tumor. Saberian et al. considered several normal tissues in their
study, however they were unable to find the closed form solution to the problem for all possible cases
and they only discussed the sufficient conditions under which equal-dosage fractionation is optimal
[36]. In [2] two simultaneous normal tissue toxicity constraints were implemented. In a very recent
work, Saberian et al. [37] found the closed form solution to the problem of optimal fractionation
while maintaining multiple simultaneous normal tissue constraints without considering any pre-
sumptions about the configuration of the optimal solution. They solved the problem to optimality
by instead solving a two-variable linear program with two additional nonlinear constraints.
An important result emerging from recent work is that the sparing factor of normal tissues
and the magnitude of the α/β ratio for both normal tissues and the tumor determine the optimal
radiation schedule ([2], [27], [37] and [43]). Therefore the optimal fractionation schedule is acutely
sensitive to perturbations in these parameters. One consequence of this sensitivity is the following:
an optimal fractionation schedule will have been derived for a fixed set of parameter values (called
the nominal values), but for a specific patient with a distinctly different set of parameter values
this schedule is no longer optimal, and in fact may have poor performance. The uncertainties in
radiotherapy treatment can be categorized into two groups: geometric and inter-patient variabil-
ity. Target volumes take account of geometric uncertainties such as organ motion, inaccuracies
or variations in treatment set-up, patient positioning errors and fluctuations in machine output.
Several studies addressed these uncertainties using different techniques. Stroom et al [39] devel-
oped a method for the automatic calculation of planning target volume margins as a means for
incorporating geometric uncertainties in the region that is irradiated. The traditional approach to
dealing with uncertainty in IMRT (considering a margin surrounding the tumor volume) increases
the radiation exposure of healthy tissue. Chan et al. [8] developed a robust framework to incorpo-
rate uncertainty in the probability distribution that describes breathing motion, and showed that
a treatment plan obtained from the robust formulation delivers 38% less dose to the OARs than
the traditional solution, while providing the same level of protection against breathing uncertainty.
In a similar work, Chu et al. [9] used a robust optimization approach to find the IMRT treatment
plans while considering patient motion and setup uncertainties. More specifically they included
uncertain voxel location in their model and as a consequence the delivered dose became a random
variable. They designed a mathematical model constructing plans that are more adept at sparing
healthy tissue while maintaining the prescribed dose to the target under uncertainty. In [42], two
methods to account for range uncertainties, one method using a probabilistic approach and the
other applying methods from robust linear programming were presented to find optimized treat-
ment plans for intensity modulated proton therapy. Both methods greatly reduced the sensitivity
to range uncertainties of the resulting treatment plans. A modification of the worst case optimiza-
tion was applied to a clinical case by Pflugfelder et al. [32]. In addition to the robust optimization,
stochastic programming has also been used to account for organ motion and setup errors in IMRT
optimization (see [22], [23]), e.g. Unkelbach developed a planning method that accounts for the
probabilistic dwelltime of a tumor evaluated from multiple CT scans [44].
Inter-patient variability is due to heterogeneity in patient-specific variables such as the sen-
sitivity of their normal tissues and tumor to radiation, and the growth rate of their tumor. In
several cancers there have been multiple subtypes discovered driven by distinct genetic pathways
and having distinct phenotypic behaviors such as growth parameters and response to therapy (e.g.
glioblastoma [28], breast cancer [29], head and neck cancer [12], melanoma [26] and many others).
A distinct possibility is that there is still significant patient variability within these subtypes. In
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fact this inter patient heterogeneity is a large reason for the pursuit of personalized medicine [18].
Given current technologies it is difficult to measure tumor response parameters α and β during
treatment due to confounding effects such as protracted cell death [14], cell cycle arrest [4], and
radiotherapy mediated immune response [20]. Furthermore, toxicity effects often do not show up
until several months or even years after conclusion of therapy, and it is therefore not possible to
learn the tumor response properties of normal tissues during treatment. In this paper we concen-
trate on the modeling the uncertainties arising in inter-patient variations, which we will use later
in an optimization method for radiotherapy scheduling. In a recent unpublished manuscript [1]
(appearing on web after the first version of current manuscript), the authors developed a similar
model where the uncertain parameters is assumed to take values in a given interval. Unfortunately
this optimization method may lead to an overly pessimistic solution, and furthermore they did not
include the uncertainty in the tumor radio-sensitivity parameters (α and β). To the best of our
knowledge, the present study is the first to address the stochastic and linear uncertainty generated
by inter patient heterogeneity.
We present a mathematical formulation of the optimal fractionation problem in the presence of
multiple normal tissues incorporating uncertainties in model parameters based on the LQ model
adjusted for tumor proliferation with a time lag. This formulation allows for the parametric uncer-
tainty to take two forms. First a minimal underlying stochastic model of the uncertain parameters
is assumed to be known and every parameter, independently of other entries, takes values in a given
interval. We formulate our problem as a model whose solution must be feasible for all realizations
of the parameters, and even a small violation of the constraints cannot be tolerated. This method
may lead to an overly pessimistic solution, therefore we develop additional models where we assume
that the uncertain parameters are characterized by a probability distribution and we reformulate
our optimization problem to now insure that our constraints are satisfied with a given probability,
and that our objective function achieves a desired level with a given probability. We examine the
mathematical properties of the optimal fractionation scheme in various models. The results are
discussed in the context of head and neck tumors. As a generalization, we broadly consider the
effects of parametric uncertainty on the structure of optimal fractionation schedules.
The organization of the remainder of the paper is as follows. In section two we describe the
problem formulation in the setting of fixed parameters (the nominal setting), and then formulate
the robust and probabilistic counter parts of this nominal problem for various uncertainty sets. In
the next section we describe our solution methods for the problems presented in section two. In
section four we solve our optimization problems for the specific case of head and neck carcinomas
and generalize the results to the other tumors. In section five we summarize our results and discuss
the implications of our findings.
2 Model of uncertainty and robust formulation
In this section, we first define an objective function derived from the standard linear-quadratic
model of radiotherapy response. We next discuss the constraints that are present in our optimization
problem, which are derived by maintaining a fixed level of normal tissue damage for a variety of
tissue types. Finally we incorporate parameter uncertainty by formulating robust and probabilistic
versions of our optimization problem.
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2.1 The nominal formulation
We now consider the problem of finding fractionation schedules that lead to maximal tumor re-
duction while maintaining acceptable levels of normal tissue damage. The basic linear quadratic
(LQ) model states that if a collection of tumor cells are exposed to N fractions of radiation with
dj Gy (SI derived unit of ionizing radiation) in j
th fraction, the reproductively viable fraction of
cells is given by e−
∑N
j=1 αdj+βd
2
j . However, reproductively viable tumor cells will eventually begin
to reproduce, and thus the total surviving fraction of surviving cells is often adjusted to take into
consideration the reproduction of tumor cells. A common way to model the repopulation effect
is to assume an exponential repopulation process, see e.g., [40]. Thus the net surviving fraction
(S) due to combined effects of radiation and repopulation after the conclusion of a fractionated
radiotherapy treatment is given by
S = e−
∑N
j=1 αdj+βd
2
j e
ln(2)(Tr−Tk)+
Te
where Tr, Te and Tk are respectively radiation delivery duration, effective cellular doubling time
and kick-off time (or lag before exponential growth begins). The expression (Tr − Tk)+ is defined
as max(0, Tr−Tk). Throughout this paper, we made two important assumptions. First in order to
consider the impact of working hour constraints on the objective function, we assume that working
hour constraints require that radiation can only be delivered hourly between 8 am and 8 pm and
five days per week. Second, we assume for every schedule there exist n daily fractions with equal
time elapsed between consecutive fractions. If we define a and r as the quotient and remainder of
N
n , respectively, and a
′ and r′ as the quotient and remainder of a5 , respectively, we can compute Tr
as (2.1) when a 6= 0. When a = 0, we simply have Tr = 8+12
r−1
n−1
24
Tr =

7a′ + r′, r = 0, r′ 6= 0
7(a′ − 1) + 5, r = 0, r′ = 0
7a′ + r′ +
8+12 r−1
n−1
24 , r ≥ 1, r′ 6= 0
7(a′ − 1) + 5 + 8+12
r−1
n−1
24 , r ≥ 1, r′ = 0
(2.1)
A natural risk associated with radiotherapy is damage to normal tissue near the tumor. A
further complication to this toxicity is that in any radiotherapy treatment there are often a large
number of normal tissues exposed to radiation. In addition to the existence of a large number of
normal parenchymal cells in the clinical target volume of the respective organ, all tumor volume
contains various stromal tissues (e.g. blood vessels and normal connective tissue). In all these
normal cells and structures, radiation side-effects may be different (e.g. see the effect on radiation
on parallel, serial and dose-volume organs in [19]). A common measure of toxicity for various
normal tissues is the biologically equivalent dose or BED [11]. In particular, assume that for a
specific normal tissue of interest the radiation response is characterized by parameters αi and βi,
furthermore assume that this tissue is exposed to N fractions of sizes {d1, . . . , dN} respectively, and
lastly assume that for fraction j normal tissue is only exposed to δidj Gy of radiation for a sparing
factor δi ∈ (0, 1]. For each normal tissue we define the maximal toxicity
BEDmaxi = Di + δi
βi
αi
D2i
Ni
where Di and Ni are tissue specific parameters. Note that Di is a tissue specific parameter, e.g. it
is defined as maximum total dose for the serial normal tissues and maximum mean dose in parallel
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normal tissues [36]. The toxicity constraints for all the OAR is then given by
N∑
j=1
(dj +
βi
αi
δid
2
j ) ≤ BEDmaxi for 1 ≤ i ≤M, (2.2)
where M is the number of different normal tissues under consideration. By taking the natural
logarithm of objective function and using (2.2) to model acceptable normal tissue damage, the
nominal problem of finding fractionation schedules that lead to maximum tumor damage while
maintaining acceptable levels of normal tissue damage can be modeled as
max
dj≥0,N∈Z+
N∑
j=1
αdj + βd
2
j − g(N) (2.3)
subject to
N∑
j=1
(dj +
βi
αi
δid
2
j ) ≤ Di + δi
βi
αi
D2i
Ni
, i = 1, . . . ,M
where g(N) = ln(2)[Tr−Tk]
+
Te
.
2.2 Modeling uncertainty in radiobiologic parameters
In order to solve the optimization problem (2.3) it is vital to know the parameters α, β, βi/αi, and δi
since the optimal fractionation schedule will depend on their value ([2], [27] and [43]). However, it is
quite difficult to obtain accurate measurements of these parameters in a clinical setting and precise
estimates of these values are very difficult to find. Furthermore, due to inter-patient heterogeneity
it is possible that a wide range of parameter values are possible across the patient population. For
example in several cancers there are a multitude of possible mutational pathways responsible for
the creation of the tumor, e.g., breast, glioblastoma, and head & neck. As a result of this situation
we are investigate the effect of parametric uncertainty on the solution to problem (2.3).
We assume uncertainties presented in LQ model can take two forms: (i) estimation errors for
parameters of constant but unknown value, and (ii) stochasticity of random variables. In the first
case only the range of the uncertain parameters is known, specifically, we assume parameter a
belongs to a symmetric interval [a¯− la, a¯+ la] centered at a¯ and for the second scenario we consider
a as a continuous random variable with probability density function f . In the second case, we are
interested in finding the optimized radiotherapy delivery schedule based on two principles: first the
nominal values of sensitive parameters are inaccurate and we only know that they lie in a given
and second, using the range alone may lead to an excessively high level of conservativeness and the
the objective function may suffer as a result.
2.2.1 Non-probabilistic robust formulation
As mentioned above the parameters α, β, {δi}Mi=1 and {βi/αi}Mi=1 are subject to uncertainty and
may vary amongst patients. For example the values 0.33Gy and 0.10Gy are frequently assumed for
the ratio β/α for late responding normal tissue and tumor tissue respectively. However these values
should be considered as a rough estimate as there is little evidence [19] to show that these values can
be generalized across a wide range of human normal-tissue endpoints and tumor histologies. For the
sparing factor δ, there has been a significant amount of effort dedicated to improving the accuracy
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and precision of radiation therapy delivery in the past decades. However there still exist sources
of uncertainty (e.g., patient motion, organ deformation, positioning uncertainty) which make it
impossible to achieve full precision in estimating parameters associated with organ movements in
radiotherapy, and thus the exact value of the sparing factor δ is often not known.
Here our aim is to construct a robust formulation to (2.3) that is immune to realizations of
the uncertain parameters so long as they lie within certain sets. This approach may be the only
reasonable alternative when the parameter uncertainty is uniformly distributed, or if no distribu-
tional information is available. First we consider the case that the values of parameters α and β
are known and we only know that the parameters {βi/αi}Mi=1 and {δi}Mi=1 lie in given intervals.
These uncertainty sources can have a detrimental effect on configurations or feasibility of optimal
schedules. In this paper, we assume a fixed amount of radiation are delivered to tumor, however
the fraction of radiation absorbed by normal tissues is subject to uncertainty. Here we assume for
the ith normal tissue, βi/αi and δi are modeled as symmetric and bounded random variables that
take lie in given intervals, or equivalently
βi
αi
∈ [ β¯i
αi
− li, β¯i
αi
+ li], and δi ∈ [δ¯i − lδi , δ¯i + lδi ], i ∈ {1, . . . ,M}. (2.4)
Formally, the robust counterpart of (2.3) considering uncertainties defined in (2.4) can be written
as
max
dj≥0,N∈Z+
N∑
j=1
αdj + βd
2
j − g(N) (2.5)
subject to
B1 ∩ B2 ∩ · · · ∩ BM−1 ∩ BM
where the definition of B1, . . . ,BM and the derivation of the robust counterpart can be found in
the appendix.
2.2.2 Probabilistic optimization models
Although (2.5) provides the strongest protection against excessive toxicity in OAR, it is also the
most conservative solution and results in less tumor cell kill than achieved by optimizing the
nominal formulation. To address this excessive conservativeness, we control the level of flexibility
between robustness and performance of the optimal schedule by using a probabilistic formulation
that provides a notion of a budget of uncertainty. We view α and β as continuous random variables
with joint probability density function f(·, ·) and we assume that the cdf of βiαi and δi in the ith
normal tissue are Fi and Gi respectively. In addition we assume that for each i
βi
αi
and δi are
independent of all other random variables in the model. We will require that BED in the ith
normal tissue does not exceed some level with a high probability. This desire can be naturally
expressed by requiring that the BED in the ith normal tissue exceeds the maximum allowable
BED, BEDmaxi , with probability at most 1 − pi, where pi is some constant close to 1, e.g., 0.95.
Furthermore we require that optimized schedules obtained by our robust formulations result in an
objective value which exceed level z, with probability more than or equal to pz. Computing the
above probabilities, we can derive
max
dj≥0,N∈Z+,z
z − g(N) (2.6)
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subject to ∫ z∑N
j=1
dj
0
∫ z−α∑Nj=1 dj∑N
j=1
d2
j
0
f(α, β)dβdα ≤ (1− pz)P (α ≥ 0, β ≥ 0)
S1 ∩ S2 ∩ · · · ∩ SM−1 ∩ SM .
Derivation and the definition of S1, . . . ,SM are shown in the appendix.
3 Solution approach
We now turn our attention to the solution of the optimization problems presented in the previous
section. For any fixed N , the feasible regions of models described in Section 2 are compact sets
and the objective functions are continuous. Therefore by the extreme value theorem of Weierstrass
[33], optima exist.
First we use the variable transformation described in [37] to simplify the formulations posed in
(2.3), (2.5), and (2.6). The simplification is to introduce the variables
X =
N∑
j=1
dj , Y =
N∑
j=1
d2j . (3.7)
We can use the results of [37] and conclude that there is a feasible solution for (3.7) if and only
if X2 ≤ NY and X2 ≥ Y . As a consequence, by adding these constraints, we guarantee that the
optimal doses d∗i can be retrieved based on the solution of the adjusted formulations.
The proliferation term, g(N), does not depend on dose. By including tumor proliferation, we
can also optimize the number of treatment sessions N . This can be done by first introducing the
maximum number of radiation fractions we are willing to administer in the course of radiation
therapy, Nmax. The for each 1 ≤ N ≤ Nmax we solve the simplified versions of problems posed
in (2.3) and (2.5) using transformation introduced in (3.7) and the two additional constraints
X2 ≤ NY and X2 ≥ Y . Finally, we choose the N that maximizes the optimal biological effect on
the tumor and return the optimal (X∗, Y ∗) associated with the optimal N as the global optimal
solution.
The feasible region defined by each Bi or Si using the transformations in (3.7) can be described
in the following simplified form{
Y ≥ D
2
i
Ni
, X + ciY ≤ Di + ciD
2
i
Ni
}
∪
{
Y ≤ D
2
i
Ni
, X + c′iY ≤ Di + c′i
D2i
Ni
}
, i = 1, . . . ,M (3.8)
where ci and c
′
i are the coefficients from Bi or Si. When α and β are fixed, for every N , we can replace
the conditions X2 ≤ NY and X2 ≥ Y with Y ≥ θNX and Y ≤ θ1X (see [37]), respectively, where for
1 ≤ k ≤ Nmax, θi = Y (k)X(k) and the pair (X(k), Y (k)) are the coordinates of the intersection kY = X2 with
polygon defined by the OAR constraints given by (3.8). Therefore in order to solve the optimization problems
(2.5) and (2.6) with a fixed value N ∈ {1, . . . , Nmax}, we need to specify the corners of the convex hull defined
by the inequalities in (3.8), Y ≥ θNX and Y ≤ θ1X. In the appendix, Algorithm 1 describes how to construct
the corners of the polygon sorted in increasing order of their x-coordinates CHN = {(X1, Y1), . . . , (Xk, Yk)}.
The optimal solution to (2.3) and (2.5) for every N occurs at one of these corners.
For (2.6) a more specialized approach is required. The new formulation of (2.6) is
max
X,Y≥0,z
z − g(N) (3.9)
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subject to ∫ z
X
0
∫ z−αX
Y
0
f(α, β)dβdα ≤ (1− pz)P (α ≥ 0, β ≥ 0) (3.10)
S1 ∩ S2 ∩ · · · ∩ SM−1 ∩ SM (3.11)
X2 ≤ NmaxY (3.12)
X2 ≥ Y (3.13)
In the rest of this section, we will present a method for solving (3.9)-(3.13). Consider a constrained
optimization problem as
max f(x), x ∈ Rn,
subject to gi(x) ≤ 0, i = . . . ,m
then we define the ith constraint to be active (at a solution y) if gi(y) = 0. We will now show that in
optimality, (3.10) is active and the optimal solution always lies on the most restrictive constraint(s), i.e., the
constraint(s) that impose the largest restriction on the dose that can be delivered to the tumor.
Lemma 1. The optimal X∗ and Y ∗ in (3.9) lie on the feasible boundaries of the region defined by
(3.11)..(3.13) and furthermore constraint (3.10) is active in optimality.
We provide the proof of this result in the appendix. Now we discuss the impact of adding X2 ≤ NmaxY
and X2 ≥ Y on optimal solutions of (3.9).
Lemma 2. At the optimal solution to (3.9), the constraints X2 ≤ NmaxY and X2 ≥ Y are either inactive
or the optimal solution occurs at corners (X(1), Y (1)) and (X(Nmax), Y (Nmax)).
The proof of this result is provided in the appendix. As a direct result of Lemma 1 and Lemma 2,
we know that the optimal pair (X∗, Y ∗) lie along the feasible boundary of the convex hull CHNmax . For
each feasible pair we can find the unique value zˆ(X,Y ) that gives equality in (3.10). Thus to solve the
optimization problem we find the pair (X,Y ) on the feasible boundary that maximizes the function zˆ(X,Y ).
In order to solve problem (3.9) we can find zˆi = zˆ(Xi, Yi) for each 1 ≤ i ≤ k, and then look at
max{zˆi − g(N) : 1 ≤ i ≤ k}. This process will tell us the optimal corner, but it does not necessarily tell
us the optimal pair (X∗, Y ∗). In order to find the optimal pair it is necessary to consider the edges of the
polygon because it is possible to construct numerical examples where the optimal solution does not occur at
a corner. Note that point (Xi, Yi) in CHNmax is only connected to the points (Xi−1, Yi−1) and (Xi+1, Yi+1),
where (X0, Y0) ≡ (Xk, Yk) and (Xk+1, Yk+1) ≡ (X1, Y1).We therefore define the vector valued function for
1 ≤ i ≤ k
(Xi(t), Yi(t)) = (tXi + (1− t)Xi+1, tYi + (1− t)Yi+1), 0 ≤ t ≤ 1,
and the inverse function
zi(t) = {z − g
(dXi(t)2/Yi(t)e) |∫ zXi(t)
0
∫ z−αXi(t)
Yi(t)
0
f(α, β)dβdα = (1− pz)P (α ≥ 0, β ≥ 0)}. (3.14)
Note that the value of z in (3.14) for every pair (Xi(t), Yi(t)) can be computed using bisection method.
The minimum number of treatment sessions for a given (X,Y ) is dX2/Y e, thus g (dXi(t)2/Yi(t)e) computes
the reproduction effect for every (Xi(t), Yi(t)). We use Algorithm 2 in appendix which is designed based on
the branch and bound approach to find the optimal solution of (3.9). On each edge of feasible region, the
branching is done on variable t and the global optimal solution is found via searching through all sub-optimal
solutions on each edge. The choices for upper and lower bounds in each subproblem is given in the appendix.
The optimal number of treatment sessions for an optimal pair of (X∗, Y ∗) is N∗ = d(X∗)2/Y ∗e.
The previous result shows how the solution (X∗, Y ∗, N∗) to the simplified versions of problems posed in
Section 2 can be found. In [37], authors proved that (X,Y ) transformation is indeed possible and is without
loss of optimality. Moreover, we can derive optimal {d∗1, . . . , d∗N} with the following result.
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Theorem 3. Optimal solution of {d∗1, . . . , d∗N} retrieved from (X∗, Y ∗, N∗) takes one of the following two
forms.
1. N∗Y ∗ = (X∗)2 for some N∗ ∈ {1, . . . , Nmax}. In this case optimal schedule is given by d∗i = X∗/N∗
for i = 1, . . . , N∗. Note that if N∗ = 1 then the schedule is hypo-fractionated, and if N∗ > 1 then the
schedule is hyper-fractionated.
2. (X∗)2/Y ∗ is not an integer: In this case, the optimal solution given by the following. Choose a positive
integer j less than (X∗)2/Y ∗ and set
d∗1 = · · · = d∗j =
jX∗ +
√
(N∗ − j)(jN∗Y ∗ − jX∗2)
jN∗
, d∗j+1 = · · · = d∗N∗ =
X∗ − jd∗1
N∗ − j . (3.15)
The proof of above result can be found in the appendix.
4 Results
In this section, we first discuss the effect of uncertainty on the structure of the optimal schedule. Then the
application of nominal and robust optimization to the treatment of head and neck tumors via radiotherapy
will be discussed. We will describe the data set and parameters that were used in our numerical experiments,
then the solution to the nominal and robust optimum dosing schedules will be explored. At the end of this
section the sensitivity of the optimal solution to model parameters is studied.
4.1 Effect of uncertainty on the optimal solution
Here we study the effects of parametric uncertainty by considering what happens to the optimal solution
when the linear and stochastic robust formulations are used instead of the nominal formulations. We use
(Xn, Yn, Nn) and (Xr, Yr, Nr) to denote the optimal solutions to the nominal and robust (either stochastic
or linear) problems. Throughout this subsection, we assume that the nominal and mean values of βi/αi and
δi are equal to β¯i/α¯i and δ¯i, respectively and the probability pi is greater than 50%. By imposing these two
assumptions the feasible region of stochastic and robust problems becomes a subset of the feasible region of
nominal problem (see Figure 2). Note that the results presented in followings are valid only if we do not allow
uncertainty in α and β (using same objective function as (2.3)). We will study the effects of uncertainty in
α and β in the specific context of head and neck cancer in the next section.
The feasibility region in the nominal formulation (2.3) is defined by several inequalities. Note that
after using the transformation (3.7), these become linear inequalities. By introducing linear or stochastic
uncertainty every line segment associated with each inequality will be broken down into two line segments
with different slopes where each segment passes through (Di,
D2i
Ni
). There are different possibilities, depending
on the amount of uncertainties in model parameters, slope of objective function (α and β), reproduction rate
of the tumor and tumor kick-off time, for how the optimal solution of the robust and stochastic problems
relates to the optimal solution of the nominal problem. The feasible region of (2.5) and (2.6) can have either
more, less or the same number of corner points as compared to the feasible region of (2.3) (see Figure 2).
We have three different scenarios for the robust or stochastic optimal schedule.
1. Nr < Nn: In this case we require that the total dose delivered to the tumor decrease, i.e., Xr < Xn.
However we may have an increase or decrease Yr depending on the parameters (compare Figure2-A
and 2-B).
2. Nr > Nn: Here we always have Yr < Yn. We can not say much about Xr and it may be greater or
smaller than Xn (compare Figure 2-A and 2-C).
3. Nr = Nn: In this case since the feasible regions of (2.5) and (2.6) are subsets of the feasible region of
(2.3), we require that the total dose and total dose squared delivered to the tumor decrease or stay
same. If for two normal tissues, i and j, we have Di = Dj , Ni = Nj and (Xn, Yn) = (Di,
D2i
Ni
), then
10
if the corner (Xn, Yn) stays feasible after adjusting feasibility region based on model uncertainties, we
will have Xr = Xn and Yr = Yn (see Figure 2-A and 2-D).
To help illuminate the reasoning behind these ideas we give a short proof of (2).
First note that the optimal solution satisfies the condition X2 ≤ NY . We know that the objective
function is decreasing in N , thus the optimal N will be the smallest integer satisfying the constraint X2 ≤
NY , i.e. Nn = d(X∗)2/Y ∗e.
Let m∗ = X2∗/Y∗ where (X∗, Y∗) are the optimal pair for the nominal problem and note that m∗ is
not necessarily an integer. Assume Nr > Nn and then obviously Nr > Nn ≥ m∗. For any real number
m1 ∈ (Nr − 1, Nr], let (X1, Y1) be the intersection of line X2 = m1Y with the feasible region of the nominal
problem. Since m1 ≥ Nn and the slope of line segments constructing this feasible region are negative, then
we have Y1 ≤ Y∗. Next define (X2, Y2) as the intersection of the line X2 = m1Y with the feasible region
of the stochastic/robust problem. Since the feasible region of stochastic/robust problem is a subset of the
feasible region of the nominal problem defined by line segments with negative slopes, then we have Y2 ≤ Y1.
Since it is true for every m1 ∈ (Nr − 1, Nr], then we can set m1 = X2r /Yr, and thus conclude Yr ≤ Y1 ≤ Y∗.
A similar argument shows that if Nr < Nn, then we have Xr < X∗.
For model (2.5), the changes in Xr and Yr depend on both Nr and the amount of uncertainty in model
parameters. Larger uncertainties (large li) result in larger reductions. In model (2.6), these reductions not
only does depend on Nr and the amount of uncertainty (defined by the variance of uncertain parameters)
in the random variables, but also a key factor is the risk tolerance of the decision maker which is defined by
pi. If we have pi 6= 1, the reduction in (Xr, Yr) in (2.6) is smaller than (2.5).
4.1.1 Hyper vs Hypo-Fractionation
One interesting question we can investigate is, when is a hyper-fractionated schedule preferable, and how does
this compare to the setting without parameter uncertainty? In order to answer this question we make some
simplifying assumptions. First we ignore tumor repopulation, and second we assume that there is tumor radio
sensitivity parameters α and β are deterministic (i.e., known values). If pi > 0.5 and P (δi(βi/αi) ≤ 0) ≈ 0,
then we will have following different scenarios.
• If (α/β) ≤ min1≤i≤M 1/bi, then a hypo fractionated schedule is optimal.
• If (α/β) ≥ max1≤i≤M 1/b′i, then a hyper fractionated schedule with Nmax fractions is optimal.
• If min1≤i≤M 1/bi < (α/β) < max1≤i≤M 1/b′i, either a hypo or a hyper or an unequal multiple dosage
solution can be optimal.
The constants bi and b
′
i are related to the distributions of βi/αi and δi and are defined in the appendix.
In the nominal setting in the absence of tumor reproduction, [37] showed the following.
• If (α/β) ≤ min1≤i≤M (α¯i/β¯i)/δ¯i, then a hypo fractionated schedule is optimal.
• If (α/β) ≥ max1≤i≤M (α¯i/β¯i)/δ¯i, then a hyper fractionated schedule with Nmax fractions is optimal.
• If min1≤i≤M (α¯i/β¯i)/δ¯i < (α/β) < max1≤i≤M (α¯i/β¯i)/δ¯i, either a hypo or a hyper or an unequal
multiple dosage solution can be optimal.
Based on the previous two sets of results we see that we are using 1/bi or 1/b
′
i instead of (α¯i/β¯i)/δ¯i.
Since pi > 0.5, it means 1/bi < (αi/βi)/δi < 1/b
′
i, therefore we are making mini{(α¯i/β¯i)/δ¯i} smaller and
maxi{(α¯i/β¯i)/δ¯i} greater. The result of this is that we increase the chance of having mini(1/bi) < (α/β) <
maxi(1/b
′
i), where either a hypo or a hyper or an unequal multiple dosage solution can be optimal.
4.2 Application to head and neck tumors
In order to estimate head and neck tumor radiobiologic parameters, we use the data set in [34]. To improve
estimation accuracy, trials with the same properties such as total dose administered, number of fractions
and treatment duration were merged. Model fit is carried out by minimizing the weighted error between the
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model predictions of survival probability and the observed values of survival probabilities in trials associated
with different schedules. In particular, the results of K trials have been considered. The trial outputs are
survival fraction for each trial f1, . . . , fK . We assume that the tumor cell population regrows exponentially
after irradiation with a time lag of Tk and rate γ. Then following fractionated radiotherapy with X =
∑N
i=1 di
and Y =
∑N
i=1 d
2
i , the population of tumor cells T units of time after start of therapy is given by
N(T ) = N(0) exp[−αX − βY ] exp[γ(T − Tk)+]. (4.16)
As a simplification we say that recurrence is only detectable if N(T )/N(0) ≥ 1, i.e., if the tumor is bigger
than its size at the start of therapy. There are K total trials and the total radiation in trial i is Xi and the
sum of the doses squared in trial i is Yi, and that the radiotherapy lasted for Tri days. Then from (4.16) we
want to choose the distribution of α and β such that for each 1 ≤ i ≤ K
P (exp[−αX − βY ] exp[γ(T − Tk)+] ≤ 1) = fi
Assume that the distributions of α and β are characterized by the joint density f(x; y; θ) where θ is a
parameter that specifies the distribution. We define the probability that (α, β) take values in some set as
(with the θ dependence explicit)
Pθ(a1 ≤ α ≤ a2, b1 ≤ β1 ≤ b2) =
∫ a2
a1
∫ b2
b1
f(x, y; θ)dxdy.
We assume that θ takes values in the space Θ. For each trial 1 ≤ i ≤ K we define function
φi(θ) = Pθ(exp[−αXi − βYi] exp[γ(T − Tk)] ≤ 1).
Then our procedure for finding the best parameter set is to solve the minimization problem
min
θ∈Θ
K∑
i=1
ni(φi(θ)− fi)2
where ni is the number of patients in i
th trial. Simulated annealing algorithm is utilized to find the optimal
values of above model. We assume that the radiosensitivity parameters of LQ model, α and β are distributed
based on two independent normal distributions with means µα and µβ and standard deviations σα and σβ ,
respectively. The reproduction rate γ (= ln(2)Te ) and Kick-off time, Tk, for head and neck were selected to be
0.003 per day and 21 days respectively [34]. The parameter T was set to be 5 years and the nominal values
of α and β were set to be equal µα and µβ . All parameters are summarized in Table 1.
We consider six different normal tissues involved in the treatment of head and neck carcinomas ([7] and
[38]). The nominal values and confidence intervals for β/α for various normal tissues were extracted from
[35], [41], [10], [25], [30], [46], [24] and [31] and are listed in Table 2. We assume that the ratio of {βi/αi}i=Mi=1
for normal tissues are distributed based on normal distributions with means µ(β/α)i and standard deviations
σ(β/α)i . The values of means µ(β/α)i were set to the average of lower bound and upper bound of confidence
intervals reported in above references. Also the standard deviation of {βi/αi}i=Mi=1 associated with different
normal tissues were computed based on their confidence intervals given in references. Normal distributions
with parameters µδi and σδi are considered for {δi}i=Mi=1 . Mandible and spinal cord are considered as serial
structures and the data reported in [13] is utilized to compute their distribution parameters. Brain stem
and parotid glands are assumed to be a serial and parallel tissues, respectively, and their parameters are
estimated from data reported in [38]. In these papers, average and standard deviation of dose absorbed by
a normal tissue for a given dose radiated to the tumor are reported. In [7], the values for planned dose,
actually delivered dose and re-planned dose have been reported. We used these values to obtain a range for
sparing factors for larynx and skin. Skin is considered a serial structure and larynx is considered a parallel
structure. Nominal values of {βi/αi}i=Mi=1 and sparing factors are set to the µ(β/α)i and µδi , respectively.
The tolerance dose values for various normal tissues were computed from [11], delivered in 35 fractions. We
assume that patients may be treated at most in seven weeks and they visit the clinics three times a day,
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n = 3. By considering 5 working days every week, we can compute the maximum number of allowable
fractions as Nmax = 7× 5× n = 105.
In order to understand the effects of parametric uncertainty on the structure of the optimal schedule,
we consider one additional setting for β. In particular we change the values of µβ and σβ to 0.0001 (we
call this scenario case 2 and the original values are case 1). The consideration of small values for β enables
us to study the effect of uncertainty on schedules with a large number of fractions. The maximum dose
constraints of 32 Gy for parotid glands results in optimal schedule with small values of total dose. Since in
clinical practice larger dose has been used, we report optimal solution for two cases, including parotid glands
in our constraint set and excluding it. Table 3 displays the optimum schedule for different models (optimal
doses can be calculated from Theorem (3)). Our numerical results for head and neck tumor show that
the presence of uncertainty changes the optimal schedule to a schedule with larger dose delivered in more
fractions (smaller total dose squared) for case 1 and almost same total dose delivered in smaller fractions
for case 2. As expected, the value of the objective function z∗ in (2.6) is decreasing in the probability of
having the actual tumor BED less than the optimal value of z∗. The z∗ value drops from 18.01 to 6.22 if we
increase pz from 50% to 90%.
Figure 3 plots the N∗ in (2.6) for different values of γ = ln(2)Te . The optimal value of the objective function
is a non-increasing function in γ. For short schedules, since the proliferation effect is negligible g(N) ≈ 0,
the objective solution is robust to drifts in γ. However in fast growing tumors, long treatment times have a
negative effect on the treatment outcome.
5 Conclusion
In this work, we have analyzed the problem of finding optimal radiation administration schedules considering
various types of normal tissues in the presence of model parameter uncertainty. In particular, we aimed to
identify the optimized total dose, number of fractions, dose per fraction and treatment duration for a variety
of formulations considering different types of uncertainty. We used the traditional linear quadratic model
including tumor proliferation to investigate the dynamics of radiation response considering two uncertainty
sets. First we assumed that only a range of possible values is known for the model parameters, βα and sparing
factors of normal tissue, δ, are known. We presented robust formulations of our optimization problem that
are immune to realizations of the uncertain parameters so long as they lie within their respective ranges.
Since using the ranges alone may lead to an excessively high level of conservativeness, in the second phase,
we adjusted our formulations for the cases that uncertain parameters are distributed as continuous random
variables with known probability density functions. Here we imposed the risk aversion factors in the objective
function and the feasibility of constraints using some pre-defined probabilities.
We used the transformation introduced in [37], defining the total radiation as X and sum of doses squared
as Y , and showed that our problem can be significantly simplified and easily solved in two dimensions when
uncertainty in α and β are disregarded in the problem. In this case we observed that if the constraint
X2 = NY is active in optimality, then the largest possible BED to the tumor can be given in an equal-
dosage schedule, otherwise the optimal solution is a semi-equal dosage schedule. When we consider α and β
as two continuous random variables, the problem becomes more challenging and optimal solution can happen
at a non-corner point. In this case, first we have shown that the optimal value occurs at the boundaries of the
feasible region defined by normal tissues BED constraints. We the designed a branch and bound algorithm
to solve these stochastic models to optimality. Saberian et al. [37] have recently proposed a method to
extract the optimal doses d∗1, d
∗
2, . . . , d
∗
N given X
∗, Y ∗. However their approach fails if the optimal number
of radiation sessions becomes larger than 2 and (X∗)2/Y ∗ is not an integer (note that d1 is not necessarily a
positive real number in case 3 of Theorem 1 in [37] when (X∗)2/Y ∗ > 2). Here we showed that a semi-equal
dosage schedule is optimal where d∗1 = · · · = d∗j and d∗j+1 = · · · = d∗N∗ for an integer j < X
2
Y .
As a generalization of our results, we observed that when the presence of uncertainty does not change
the structure of the optimal solution, it is preferred to administer same or smaller total dose and total dose
squared. However if we have larger (smaller) treatment sessions in probabilistic or robust solution compared
to nominal schedule, a reduction in total dose squared (total dose) will be seen.
Using data gathered previously [34], we parametrized the uncertainty in α and β to investigate the
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behavior of optimal schedules for the head and neck tumors. For the numerical results, we assumed that the
head and neck cancer site includes six normal tissues, spinal cord, brain stem, skin, mandible, larynx and
parotid glands. The uncertainties in normal tissues have been estimated based on various data sets in the
literature. The nominal optimal solution is a hypo-fractionated schedule changing to a schedule with larger
total dose delivered in more fractions in the presence of parameter uncertainty. We found that when we
consider small values of β, the optimal schedule is a hyper-fractionated schedule with maximum allowable
fractions. In this case the robust solution has an insignificant change in the optimal total dose and total
dose squared for different schedules, however the optimal number of fractions decreases in some cases. We
saw that as the tumor regrowth rate increases, shorter treatment are preferable.
There are several possible extensions to this work that we plan to consider in the future. For example,
this work does not incorporate spatial structure of the tumor, including possible spatial heterogeneities in
the parameters α and β. Another possible extension is the incorporation of repair effects, this would be
useful if we wanted to consider shorter inter fraction periods. Lastly, it would be interesting to incorporate
immune response and how inter-patient heterogeneity in immune response could impact the design of optimal
fractionation schedules (see [20]).
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6 Appendices
6.1 Derivation of the robust reformulations
6.1.1 Non-probabilistic robust formulation
In this section, we derive a computationally tractable solution to the robust optimization problem (2.3). In
the non-probabilistic robust formulation we do not allow any violation of the normal tissue constraints for
any parameters taking values in the sets (2.4). Therefore the robust counter part of (2.3) associated with
uncertainty sets defined in (2.4) is found by solving
max
dj≥0,N∈Z+
N∑
j=1
αdj + βd
2
j − g(N) (6.17)
subject to
sup

 N∑
j=1
d2j −
D2i
Ni
 δi βi
αi
∣∣∣βi
αi
∈ [ β¯i
αi
− li, β¯i
αi
+ li] and δi ∈ [δ¯i − lδi , δ¯i + lδi ]
 ≤ Di −
N∑
j=1
dj ∀i.
Note that when
∑N
j=1 d
2
j ≥ D
2
i
Ni
, the supremum happens when βiαi and δi take their upper bounds in the sets
(2.4), otherwise the supremum is achieved in lower bounds of βiαi and δi defined in (2.4). We now replace the
problem (6.17) by a formulation using the supremum of BED constraints:
max
dj≥0,N∈Z+
N∑
j=1
αdj + βd
2
j − g(N) (6.18)
subject to
B1 ∩ B2 ∩ · · · ∩ BM−1 ∩ BM
where Bi is defined as follows
Bi =

N∑
j=1
d2j ≥
D2i
Ni
,
N∑
j=1
dj + ai
N∑
j=1
d2j ≤ Di + ai
D2i
Ni
 ∪

N∑
j=1
d2j ≤
D2i
Ni
,
N∑
j=1
dj + a
′
i
N∑
j=1
d2j ≤ Di + a′i
D2i
Ni

and ai = (δ¯i + lδi)(
β¯i
αi
+ li) and a
′
i = (δ¯i − lδi)( β¯iαi − li).
6.1.2 Probabilistic optimization models
We now describe a formulation that assumes that α, β, and βiαi and δi are random variables with known
probability distributions, and we use our knowledge of this uncertainty to enforce the constraints in a
probabilistic fashion. We require that the probability of violation of the BED constraint in ith OAR is at
most 1− pi. Written mathematically we have
P
 N∑
j=1
(dj + δi
βi
αi
d2j ) ≤ Di + δi
βi
αi
D2i
Ni
∣∣∣βi
αi
≥ 0, δi ≥ 0
 ≥ pi ∀i. (6.19)
Note that from a biological point of view, it is impossible for α, β, βiαi and δi to take negative values, and
since in literature it is often assumed that these parameters are normally distributed, we need to add the
non-negatively conditions above. By knowing the cdf of βiαi and δi (recall that we assume these random
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variables are independent), we can easily compute the cdf of their product. Let Hi be the cdf of
βi
αi
δi. In
order to satisfy (6.19) for random variables δi and
βi
αi
we must have:
P
( N∑
j=1
d2j −
D2i
Ni
)δi
βi
αi
≤ Di −
N∑
j=1
dj , δi
βi
αi
≥ 0
 ≥ piH¯i(0) ∀i. (6.20)
Note that we assume δi ∈ [0, 1] and thus the event { βiαi ≥ 0, δi ≥ 0} is equivalent to {δi
βi
αi
≥ 0}. If we consider
the events in (6.20) for the positive and negative values of
∑N
j=1 d
2
j − D
2
i
Ni
, we can rewrite the condition (6.20)
as ∩Mi=1Si where
Si =

N∑
j=1
d2j ≥
D2i
Ni
,
N∑
j=1
dj + bi
N∑
j=1
d2j ≤ Di + bi
D2i
Ni
 ∪

N∑
j=1
d2j ≤
D2i
Ni
,
N∑
j=1
dj + b
′
i
N∑
j=1
d2j ≤ Di + b′i
D2i
Ni

and bi = H
−1
i (1− (1− pi)H¯i(0)) and b′i = H−1i (1− piH¯i(0)).
We require that optimized schedules obtained by our robust formulation result in an objective
value which exceeds level z, with a probability at least pz, i.e.,
P
 N∑
j=1
(αdj + βd
2
j ) ≥ z
∣∣∣α ≥ 0, β ≥ 0
 ≥ pz. (6.21)
Note that for a fixed N , g(N) is a constant and does not depend on di and therefore we can remove
it from above probability. We can simplify (6.21) to get the constraint
∫ z∑N
j=1
dj
0
∫ z−α∑Nj=1 dj∑N
j=1
d2
j
0
f(α, β)dβdα ≤ (1− pz)P (α ≥ 0, β ≥ 0).
6.2 Proof of technical Lemma 1
Proof. Assume z∗,X∗ and Y ∗ are optimal points to (3.9). If X∗ and Y ∗ lie in the interior of
the feasible region, then there exist ∆X > 0 and ∆Y > 0 such that the pair (X ′, Y ′), where
X ′ = X∗ + ∆X and Y ′ = Y ∗ + ∆Y , is a feasible solution. The left hand side of (3.10) is a
decreasing function in X and Y , therefore we can replace (X∗, Y ∗) with (X ′, Y ′) and increase z
without violating feasibility of constraints set defined in (3.10) ... (3.13). Therefore there exists a
feasible z which is strictly greater than z∗ and it contradicts the assumption that z∗ is an optimal
solution to our problem. Therefore the optima must lie on the boundaries of the feasible region.
Also if (3.10) is not active in optimality, we have∫ z
X
0
∫ z−αX
Y
0
f(α, β)dβdα < (1− pz)P (α ≥ 0, β ≥ 0)
and we can increase z without leaving feasible region which contradicts the optimality assumption.
6.3 Proof of technical Lemma 2
Proof. Let CHNmax be the feasible region of (3.9) defined by (3.11), (3.12) and (3.13). Based on
lemma 1, the optimal solution of (3.9) lies on the feasible boundaries of CNmax . If X2 ≤ NmaxY and
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X2 ≥ Y are redundant constraints ((X∗, Y ∗) obtained by ignoring these constraints satisfy these
constraints), then X2 ≤ NmaxY and X2 ≥ Y are inactive constraints in optimality. Otherwise,
consider the three corners p1 = (0, 0), p2 = (X
(1), Y (1)) and p3 = (X
(Nmax), Y (Nmax)). As we move
from p1 toward p2 or from p1 toward p3, we can increase both X and Y . At the end of two line
segments −−→p0p1 and −−→p0p2, we are at a feasible solution (p2 or p3) with maximum X and Y , and since
the objective function in (3.9) is increasing in both X and Y , we see that the maximal value of z
is obtained at either p1 or p2.
6.4 Proof of Theorem 3
Proof. To establish the result in case 1, we can easily check that equation (3.7) holds for
d1, . . . , dN∗ = X
∗/N∗ if N∗Y ∗ = (X∗)2. In the second scenario, from straightforward calcula-
tions, we observe that there is always a solution to our problem in the following form:
d∗1 = · · · = d∗j = d, d∗j+1 = · · · = d∗N∗ = w.
We can now solve for w and d in (3.7), and establish that
w =
X∗ − jd
N∗ − j
and
d =
jX∗ +
√
j2(X∗)2 − jN∗((X∗)2 − (N∗ − j)Y ∗)
jN∗
=
jX∗ +
√
(N∗ − j)(jN∗Y ∗ − j(X∗)2)
jN∗
.
It then remains to establish that d and w are non-negative real numbers. First observe that we
require that j ≤ (X∗)2/Y ∗ ≤ N∗. It follows from this that d is a positive real number, and thus
w is a real number as well. It then remains to establish that w is non-negative. This is of course
equivalent to showing that X∗ − jd > 0. Note that
X∗ − jd = 1
N∗
[
(N∗ − j)X∗ −
√
j(N∗ − j)(N∗Y ∗ − (X∗)2)
]
=
1
N∗
[
(N∗ − j)X∗ −
√
jY ∗(N∗ − j)(N∗ − (X∗)2/Y ∗)
]
and therefore
X∗ − jd > 0⇔ (X
∗)2
Y ∗
> j.
The result then follows from our conditions on the integer j.
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6.5 Algorithms
6.5.1 A Feasible Region Creator Algorithm
Algorithm 1 Constructing the corners of feasible region defined by (3.8), X2 ≥ Y and X2 ≤ NY
1: Define L1 as the set of all line segment connecting (0, Dici +
D2i
Ni
) and (Di,
D2i
Ni
) and L2 as the set of all line segment passing
through (Di,
D2i
Ni
) and (Di + c
′
i
D2i
Ni
, 0) for i = 1, . . . ,M .
2: Use Bentley-Ottmann algorithm [3] for listing all crossings in the set of {L1 ∪ L2}, call it L.
3: Let L be L ∪ {(0, Di1
ci1
+
D2i1
Ni1
)} ∪ {(Di2 + c′i2
D2i2
Ni2
, 0)} where i1 = argmink{Dkck +
D2k
Nk
} and i2 = argmink{Dk + c′k
D2k
Nk
}
4: Compute V = {(v1, v′1), . . . , (vp, v′p)}, as the set of all pairs in L satisfying (3.8) for all i = 1, . . . ,M , sorted in increasing
order by the x-coordinate.
5: CH1 ← {(0, 0)}
6: For i← 1 to p− 1
7: Compute (xi, yi) as the intersection of line passing through (vi, v′i) and (vi+1, v
′
i+1) and y = x
2.
8: If vi ≤ xi < vi+1 and yi > 0
9: index[1]← i
10: CH1 ← CH1 ∪ {(xi, yi)}
11: Break
12: End If
13: End For
14: For i← 2 to Nmax
15: CHi ← CHi−1
16: For j ← index[i− 1] to p
17: If v2j ≤ iv′j
18: CHi ← CHi ∪ {(vj , v′j)}
19: index[i] ← j
20: Else
21: if j ==index[i− 1] then index[i] ←index[i− 1], else index[i] ← j − 1
22: Break
23: End If
24: End For
25: End For
26: For i← 2 to Nmax
27: Let (xi, yi) be the intersection of x2 = iy and line passing through (vindex[i], v
′
index[i]
) and (vindex[i]+1, v
′
index[i]+1
)
28: CHi ← CHi ∪ (xi, yi)
29: End For
6.5.2 Branch and bound algorithm
Note that for every line segment defined by two points (X1, Y1) and (X2, Y2), we can compute
the lower bound using
Φlb = max{z1(0), z1(1)}
and compute the upper bound using
Φub = {z − g(dmin(X1, X2)
max(Y1, Y2)
e
∣∣∣ ∫ zmax(X1,X2)
0
∫ z−αmax(X1,X2)
max(Y1,Y2)
0
f(α, β)dβdα = (1− pz)P (α ≥ 0, β ≥ 0)}.
On each edge, the branching variable is t ∈ [0, 1]. At node i, we store the lower bound and upper
bound of t as lbt(i) and ubt(i). Similarly lower and upper bounds of optimal solution at node i are
stored in lbz(i) and ubz(i). Note that a(i) = {0, 1} indicates the state of the node in our optimization
tree, if a(i) = 1 then our node is considered as active node and further partitioning can be proceeded
through that branch, otherwise we consider that node as an inactive node. Branching in node i
continues in this manner until there are no active nodes in that branch or ubz(i)−ubz(i) < , where
 is the given accuracy for optimal value. Since the objective value of an optimal solution cannot be
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Algorithm 2 Branch and Bound algorithm for maximization of (3.9)
1: For each (Xi, Yi) ∈ CHNmax , compute zi(1) and set z∗ = zj(1) and (X∗, Y ∗) = (Xj , Yj) where j = arg maxi zi
2: For l = 1 to |CHNmax | − 1 Do:
3: i← 1.
4: lbt(i)← 0, ubt(i)← 1.
5: lbz(i) = max{z(Xl(0), Yl(0)), z(Xl(1), Yl(1))}, ubz(i) = z(max{Xl(0), Xl(1)},max{Yl(0), Yl(1)}).
6: a(i)← 1.
7: While
∑
i a(i) > 0 Do:
8: ind=find(i|a(i) > 0).
9: For j=1:length(ind) Do:
10: i← i+ 1.
11: lbt(i) = (lbt(ind(j)) + ubt(ind(j)))/2, ubt(i) = ubt(ind(j)).
12: Compute
lbz(i) = max{z(Xl(lbt(i)), Yl(lbt(i))), z(Xl(ubt(i)), Yl(ubt(i)))}, ubz(i) = z(max{Xl(lbt(i)), Xl(ubt(i))},max{Yl(lbt(i)), Yl(ubt(i))}).
13: If (ubz(i)− lbz(i) > ), then a(i)← 1, else a(i)← 0.
14: lbt(ind(j)) = lbt(ind(j)), ubt(ind(j)) = (lbt(ind(j)) + ubt(ind(j)))/2.
15: Repeat steps 13 and 14 with ind(j) instead of i.
16: Update z∗ and (X∗, Y ∗) for any lbz(j) > z∗.
17: End For Loop.
18: For every j such that ubz(j) < z∗, a(j)← 0.
19: Sort [lbt(:), ubt(:), lbz(:), ubz(:), a(:)]T column-wise based on lbt(i).
20: End While Loop.
21: End For Loop.
smaller than a lower bound, active nodes with upper bounds smaller than an existing lower bound
can be safely deleted (step 19).
Remark 1. Algorithm 2 converges and terminates with certificate proving -suboptimality.
Number of line segments in partition Lk is k. Note that total length of these line segments is
L(Qinitial), so
min
Q∈Lk
L(Q) ≤ L(Qinitial)
k
and hence for big k, at least one line segment has small length and having small length will imply
that ubz(k)− lbz(k) is small.
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6.6 Figures
Figure 1: Feasible region of optimization problems posed in section 2. A) This plot shows the
feasible region of model (2.3). For each N , the optimal solution occurs at one of the corners of
feasible region. B) This plot shows the effect of uncertainty in model parameters on feasible region.
Every line segment is broken down into two line segments with different slopes and passing through
(Di,
D2i
Ni
). If α and β are fixed, the optimal solution for every fixed N lie on one of the corners of
CHN . Having α and β as random variables, the pair (X∗, Y ∗) can be located by searching on all
line segments connecting (X1, Y 1) and (XNmax , Y Nmax).
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Figure 2: This plot shows the effect of uncertainty on the optimal solutions in the presence of
three OARs. In each subfigure the feasible region is shaded. In panel (A) we plot the feasible
region and optimal solution in the nominal case. Note we also label the points
(
D′1,
(D′1)
2
N1
)
and(
D′3,
(D′3)
2
N3
)
as alternative maximum tolerable doses. In panel (B) we consider a scenario where
the solution to the stochastic problem results in fewer total fractions, i.e., NB < Nn. In panel (C)
we consider different distributions for our uncertain parameters and we have a scenario where the
optimal number of fractions in the stochastic problem is greater than the number in the nominal,
i.e., NC > Nn. Finally in panel (D) we use the alternative maximum tolerable doses
(
D′1,
(D′1)
2
N1
)
and
(
D′3,
(D′3)
2
N3
)
and construct a scenario where the optimal number of doses is unchanged by
parameter uncertainty, i.e., ND = Nn. If the optimal number of radiation sessions stays the
same in the presence of uncertainty, it is required to deliver equal or less doses in the presence
of uncertainty (D). If we have fewer (more) treatment sessions in probabilistic or robust solution
compared to nominal schedule, a reduction in total dose (total dose squared) will be seen (B and
C).
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Figure 3: This plot shows the sensitivity of treatment session in (2.6) assuming pi = pz = 95% with
respect to tumor growth rate γ assuming Tk = 7 days. For short schedules the objective solution
is robust to drifts in γ and for fast growing tumors, long treatment time have a negative effect on
the treatment outcome.
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6.7 Tables
Parameters Values unit
µα 0.1708 1/Gy
µβ 0.0537 1/Gy
2
σα 0.2142 1/Gy
σβ 0.0812 1/Gy
2
Table 1: Head and neck tumor parameters used for finding optimal schedule
Parameters Spinal Cord Brain Stem Skin Unit
µ(β/α) 0.48 0.39 0.12 1/Gy
σ(β/α) 0.09 0.05 0.01 1/Gy
(β/α− l, β/α+ l) (0.30,0.67) (0.30,0.48) (0.09,0.14) 1/Gy
µδ 58.52% 74.92% 25.29%
σδ 2.78% 3.45% 0.75%
Di 47 Gy 50 Gy 55 Gy Gy
Parameters Mandible Larynx Parotid glands unit
µ(β/α) 0.46 0.66 0.24 1/Gy
σ(β/α) 0.05 0.30 0.07 1/Gy
(β/α− l, β/α+ l) (0.36,0.56) (0.07,1.25) (0.10,0.38) 1/Gy
µδ 67.59% 99.12% 40.45%
σδ 10.56% 0.07% 0.97%
Di 60 Gy 70 Gy 32 Gy Gy
Table 2: Normal tissue parameters
With parotid glands Without parotid glands
Parameters Formulation N∗ X∗ Y ∗ Tumor BED N∗ X∗ Y ∗ Tumor BED
Case 1
Nominal 1 13.5 182.36 12.10 1 13.5 182.36 12.10
Robust 2 14.26 139.51 9.93 35 47.00 63.11 11.42
Stochastic 3 18.34 124.23 4.36 11 31.86 95.94 5.08
Case 2
Nominal 105 33.79 10.87 5.69 105 56.26 30.15 9.53
Robust 62 32.47 17.01 5.53 105 52.82 26.57 8.95
Stochastic 54 32.48 19.80 0.90 92 52.84 30.59 1.41
Table 3: Optimal solution to problems (2.3), (2.5) and (2.6) assuming pi = pz = 95%. In case
1 we assume µα = 0.1708, µβ = 0.0537, σα = 0.2142 and σβ = 0.0812 and for case 2 we have
µα = 0.1708, µβ = 0.0001, σα = 0.2142 and σβ = 0.0001.
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